Skip to content
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
Press Release

iSchemaView and NeuroLogica Team Up to Mobilize Stroke Care Worldwide

Best-in-Class Stroke Imaging Platform and Leading Mobile CT Scanner Integrate to Accelerate Mobile Stroke Evaluation and Treatment

Share to

Best-in-Class Stroke Imaging Platform and Leading Mobile CT Scanner Integrate to Accelerate Mobile Stroke Evaluation and Treatment

Menlo Park, Calif. and Danvers, Mass. — January 22, 2019 — iSchemaView, the worldwide leader in advanced imaging for stroke, and NeuroLogica, a subsidiary of Samsung Electronics Co., Ltd. and leader in medical imaging technology, today announced a partnership to integrate iSchemaView’s RAPID™ cerebrovascular imaging platform with NeuroLogica’s portable CereTom® computed tomography (CT) scanners for use in Mobile Stroke Units (MSUs) and Intensive Care Units (ICUs) across the globe. “We are thrilled to partner with NeuroLogica and its leading mobile CT system at the forefront of MSU programs across the country,” said Anil Singhal, MD, SVP, Worldwide Operations at iSchemaView. “In addition, we are excited that our partnership allows the option of RAPID advanced imaging on CereToms in more than 500 ICUs worldwide.” The CereTom is an 8-slice mobile CT scanner that delivers high-quality, non-contrast CT, CT angiography and CT perfusion scans in a variety of patient locations. RAPID is the most advanced, fully automated and only clinically proven stroke imaging platform available. It provides intuitive and easily interpretable real-time views of brain perfusion and allows clear visualization of the cerebral arteries. In conjunction, their speed, easeof-use and fast results make CereTom and RAPID indispensable tools for MSUs and ICUs, helping medical teams make life-saving triage, diagnostic and treatment decisions. RAPID is the only brain imaging platform that is FDA-cleared for selecting stroke patients for clot removal, also known as thrombectomy. “By assessing patients in MSUs equipped with both CereTom and RAPID technologies, we will be able to swiftly identify the right course of action — on site treatment with clotbusting agents or appropriate hospital transport for thrombectomy — thereby optimizing outcomes and quality of life,” said David Webster, Chief Operating Officer at NeuroLogica. Developed by leading stroke experts, RAPID combines unmatched expert features, proprietary algorithms and machine learning to deliver the best-in-class advanced stroke imaging and analysis. RAPID provides hypoperfusion, cerebral blood volume indexes, custom notifications and thresholding — including golden-hour thresholds. And RAPID is the only system that delivers results to mobile devices in less than 90 seconds, either by mobile app or email. “This is a new frontier in stroke care. We are bringing state-of-the-art technology directly to patients, no matter where they are. This allows us to make fast, accurate assessments of their clinical status and provide effective treatment directly in the MSU or transport the patient to the appropriate hospital for expedited clot removal,” said Dr. James Grotta, Director of the Mobile Stroke Unit Consortium and Director of Stroke Research for the Clinical Institute for Research and Innovation at the Memorial Herman–Texas Medical Center.

Contact PR

Jessica Stebing

Jessica Stebing

Group Manager, Marketing Communications

stebing@rapidai.com